Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly Develops Shanghai Link (China)

This article was originally published in PharmAsia News

Executive Summary

A drug-development partnership between Eli Lilly & Co. of the U.S. and a Shanghai pharmaceuticals company reflects China's growing potential as a low-cost center for biotechnology research. Lilly will work with a unit of Hutchison China MediTech Ltd., known as Chi-Med, to develop drugs to treat cancer and inflammatory diseases. Lilly will hand over preclinical research and development on several compounds to the Chinese company. Chi-Med is a subsidiary of Hutchison Whampoa Ltd., the conglomerate controlled by Hong Kong billionaire Li Ka-shing. Complete financial terms weren't disclosed, but Lilly agreed to pay $20 million to $29 million for each compound developed through the partnership, as well as an upfront fee and continuing research support. Chi-Med would get a cut of royalties from any successful drugs developed through the collaboration. Chi-Med, whose products include a heart pill made from deer musk glands, has been drawing attention from some of the world's largest pharmaceuticals companies, eager to tap Chi-Med's research expertise, low-cost base and library of 10,000 traditional Chinese herbal compounds that may have applications in Western medicine. "The Lilly deal is a sign of the quality of the work that's being in done in China," says Ibraheem Mahmood of Investec Securities in London. "Big pharmaceutical companies can see there are research capabilities there, and a burgeoning pipeline of new products." (Click here for more - May Require Paid Subscription
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel